New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
09:09 EDTBTXBioTime, unit initiates PanC-Dx clinical development in U.S., China
BioTime and its subsidiary OncoCyte announced that OncoCyte has initiated clinical development of its bladder cancer diagnostic test, PanC-Dx, in both the U.S. and China. In the U.S., OncoCyte has entered into a clinical trial agreement with a leading medical institution with an international reputation for excellence and discovery, while in China, OncoCyte has entered into a fee-for-service agreement with China Medicine. The goal of these clinical studies is the testing of OncoCyte’s proprietary diagnostic technology in the most common type of bladder cancer, namely, urothelial carcinoma. Investigators in the collaborating institutions are collecting urine samples from patients at time of bladder cancer diagnosis as well as from those with a risk for recurrent disease. A statistical analysis of these and other results will be performed to determine the overall relative performance of OncoCyte’s PanC-Dx markers. Completion of these studies is expected by late 2014.
News For BTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 19, 2015
08:04 EDTBTXBioTime says positive interim results of blood-based cancer test to be presented
Subscribe for More Information
May 14, 2015
08:03 EDTBTXBioTime sees OncoCyte funding sufficient for operations into early 2016
BioTime and its subsidiary OncoCyte Corporation announced that OncoCyte has received a new round of financing to fund further development and commercialization activities for its cancer diagnostic products. With completion of the financing, which included a cash investment of $3.3M and conversion of $3.3M of existing debt into equity, OncoCyte has approximately $7M in cash and marketable securities, which should be sufficient to fund current operations into early 2016, the company stated.
May 13, 2015
08:04 EDTBTXBioTime unit awarded $1.6M grand from Israel's OCS
BioTime and its subsidiary Cell Cure Neurosciences announced that Cell Cure has been awarded a grant for 2015 of approximately $1.61M from Israel’s Office of the Chief Scientist to help finance the development of OpRegen, a cell-based therapeutic product that consists of animal product-free retinal pigment epithelial cells with high purity and potency. Cell Cure is now enrolling patients at Hadassah University Medical Center in Jerusalem, Israel, in a clinical Phase I/IIa dose-escalation study evaluating the safety and efficacy of OpRegen for geographic atrophy, the severe stage of the dry form of age-related macular degeneration. The Phase I/IIa clinical trial was opened in February 2015 following regulatory clearance from the U.S. FDA and the Israeli Ministry of Health. The trial consists of four cohorts and will evaluate three different dose regimens. Cell Cure expects to report interim data from the cohorts in the coming months.
May 12, 2015
09:38 EDTBTXBioTime management to meet with Oppenheimer
Meetings to be held in New York on May 14 and in Boston on May 15 hosted by Oppenheimer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use